Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Results Among 30 participants (18 in the rTMS group; 12 in the sham group) who completed the 8-week trial, the mean (SD) age was 69.8 (9.1) years; 18 (60%) were female. As the primary outcome, the change in ADAS-Cog at the eighth week was significantly different between the rTMS and sham groups (coefficient [SE], -5.2 [1.6]; P = .002). The change in CDR-SOB (-4.5 [1.4]; P = .007) and S-IADL (1.7 [0.7]; P = .004) were significantly different between the groups favoring rTMS groups. The fMRI connectivity analysis revealed that rTMS increased the functional connectivity between the hippocampus and precuneus, with its changes associated with improvements in ADAS-Cog (r = -0.57; P = .005). Conclusions and relevance This randomized clinical trial demonstrated the positive effects of rTMS on cognitive and functional performance, and the plastic changes in the hippocampal-cortical network. Our results support the consideration of rTMS as a potential treatment for AD.

Key findings

Why it matters

In this 8-week trial of only 30 participants, personalized rTMS improved cognitive and functional scores and increased connectivity between the hippocampus and precuneus compared with sham treatment. The small sample size means these results are preliminary and need confirmation in larger trials before rTMS can be considered a treatment for Alzheimer's disease.

Study details

How this study scored 71/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 71 of 100.71 of 100 points earned29 not earned

Published in a leading specialty journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (JAMA network open)
Journal's citation record 2 / 4 JAMA Network Open: journal h-index 235 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 1 / 4 30 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 4 / 7 Cited 71 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 17.8 citations a year over 4 year(s) since 2024
Impact for its field and year 4 / 6 Cited 9.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 3 / 4 Cited 71 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Duk Lyul Na: h-index 67 (OpenAlex, whole career)
Institution's track record 1 / 3 Seoul National University: institution h-index 1,053 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 38709534)
Free to read 2 / 2 Free to read
Total 71 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Jung, Y. H., Jang, H., Park, S., Kim, H. J., Seo, S. W., Kim, G. B., et al. (2024). Effectiveness of Personalized Hippocampal Network-Targeted Stimulation in Alzheimer Disease: A Randomized Clinical Trial. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2024.9220

Vancouver

Jung YH, Jang H, Park S, Kim HJ, Seo SW, Kim GB, et al. Effectiveness of Personalized Hippocampal Network-Targeted Stimulation in Alzheimer Disease: A Randomized Clinical Trial. JAMA network open. 2024. doi:10.1001/jamanetworkopen.2024.9220. PMID: 38709534.

BibTeX

@article{jung2024-38709534,
  author  = {Jung, Y. H. and Jang, H. and Park, S. and Kim, H. J. and Seo, S. W. and Kim, G. B. and Shon, Y. M. and Kim, S. and others},
  title   = {{Effectiveness of Personalized Hippocampal Network-Targeted Stimulation in Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA network open},
  year    = {2024},
  doi     = {10.1001/jamanetworkopen.2024.9220},
  pmid    = {38709534},
  url     = {https://doi.org/10.1001/jamanetworkopen.2024.9220}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments

Also tagged “double-blind”

783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Similar studies

More on Treatments

See all studies in Treatments →